Abstract
Mutations in the viral genome of SARS-CoV-2 can impact the performance of molecular diagnostic assays. In some cases, such as S gene target failure, the impact can serve as a unique indicator of a particular SARS-CoV-2 variant and provide a method for rapid detection. Here we describe partial ORF1ab gene target failure (pOGTF) on the cobas® SARS-CoV-2 assays, defined by a ≥2 thermocycles delay in detection of the ORF1ab gene compared to the E gene. We demonstrate that pOGTF is 97% sensitive and 99% specific for SARS-CoV-2 lineage BA.2.12.1, an emerging variant in the United States with spike L452Q and S704L mutations that may impact transmission, infectivity, and/or immune evasion. Increasing rates of pOGTF closely mirrored rates of BA.2.12.1 sequences uploaded to public databases, and, importantly increasing local rates of pOGTF also mirrored increasing overall test positivity. Use of pOGTF as a proxy for BA.2.12.1 provides faster tracking of the variant than whole-genome sequencing and can benefit laboratories without sequencing capabilities.
Competing Interest Statement
DDR has had or anticipates having agreements through his affiliated institution for research projects from the following industry sponsors: Altona, BD, bioMerieux, Cepheid, Cleveland Diagnostics, Luminex, HelixBind, Hologic, Qiagen, Q-Linea, Roche, SpecificDx, Talis, Thermo Fisher, and Vela. DDR has recently served or does serve as a scientific advisor for DiaSorin/Luminex, Renascent Diagnostics, Roche, and Talis Biomedical. No industry funding supported DDR's work on this study. LFW has received consulting fees from Roche Molecular Systems, Shionogi, and Talis Biomedical and has received research funding from Accelerate Diagnostics, BioFire Diagnostics, Hardy Diagnostics, and Roche Molecular Systems. RMR participated in as Sub investigator in a clinical trial for Qiagen. Funds received by the institution where the trial was performed. NDG is a consultant for Tempus Labs and the National Basketball Association for work related to COVID-19 but is outside the submitted work. ACU receives research funding from Merck; unrelated to the current study.
Clinical Protocols
https://github.com/bjklab/SARS-CoV-2_Ct_report.
Funding Statement
KGR, BJK, FB, AM acknowledge funding provided by a contract award from the Centers for Disease Control and Prevention (CDC BAA 200-2021-10986 and 75D30121C11102/000HCVL1-2021-55232), philanthropic donations to the Penn Center for Research on Coronaviruses and Other Emerging Pathogens, and in part by NIH grant R61/33-HL137063 and AI140442 -supplement for SARS-CoV-2. Additional assistance was provided by the Penn Center for AIDS Research (P30-AI045008) and in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N93021C00015. BJK is also supported by NIH K23 AI121485. DAG, GJB, FW, MKA, ACU acknowledge in part NIH funding (U01 DA053949). DDR and TZ acknowledge the Ohio Department of Health for its support of Cleveland Clinic's SARS-CoV-2 genomic surveillance. TM, KJ, NEB acknowledge funding in part through the National Institute of Heath/National Cancer Institute Cancer Center Support (Grant P30 CA008748) and Philanthropic Funds from the Burns Family. NDG acknowledges funding provided by the Centers for Disease Control and Prevention Broad Agency Announcement (75D30120C09570).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of Cleveland Clinic Foundation approved #18-318, IRB of Columbia University Irving Medical Center approved #AAT0123, IRB of the University of Pennsylvania exemption #848605, IRB of Memorial Sloan Kettering approved #18-491, IRB of Weill Cornell Medicine #20-03021671, IRB of Washington University of St. Louis approved #20211131, IRB of Yale School of Public Health approved #2000031374
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All SARS-CoV-2 viral genomes have been deposited in GISAID and/or NCBI Genbank with accession numbers or viral names listed in Table S1. dEO outlier model code and sample reproducible report are available at: https://github.com/bjklab/SARS-CoV-2_Ct_report.
